|
Published by: Espicom Healthcare Intelligence
Published: Dec. 19, 2007 - 700 Pages
Table of Contents
- VOLUME I
- Current Issues in the USA
- Authorised generics
- FTC investigation
- Moves in Congress
- PhRMA responds
- GPhA responds
- More studies, more arguments
- Senate Committee Discusses Regulatory Delays, Authorised Generics, Citizen Petitions
- Gary Buehler
- Jon Leibowitz
- Heather Bresch
- Shared exclusivity
- Industry consolidation
- Where next in the USA?
- Where next in Europe?
- Biosimilars
- Political pressure
- Access to Life-Saving Medicine Act (H.R)
- Biologics Price Competition and Innovation Act of 2007 (S.1695)
- House Committee on Oversight and Government Reform
- Henry Waxman
- Access to Generic Drugs in the Developing World: WTO Agreement
- 2003 Agreement
- TRIPS patent ruling on least-developed countries, 2002
- Canada
- European Union
- European Parliament pushes for greater access to generic drugs
- Thailand
- Brazil
- Clinton Foundation
- PEPFAR
- Current Issues in the European Union
- European Union Regulatory Reforms Take Effect, November 2005
- Product definition
- Data exclusivity
- European Commission regulations for paediatric medicines introduced in 2007
- Enlargement of the European Union
- Parallel Trade in the enlarged EU
- The widening influence of Indian companies
- Prospects for Future Growth
- Relative strength of intellectual property laws
- Pricing/reimbursement regimes
- Prescriber/patient habits
- Major Generic Manufacturers
- Actavis
- Introduction
- Background
- Products
- Own-label Products
- Third-Party Products
- Financials
- Segment Data
- Major developments
- Actavis building new R&D centre in Iceland
- Actavis opens Albania office
- Actavis opens a representative office in Vietnam
- Mergers, acquisitions and agreements
- Actavis partners with Germany’s AOK
- Actavis acquires Indian manufacturing plant
- Actavis and Orchid form European licensing and distribution alliance
- Actavis strengthens its position in India
- Actavis acquires Abrika
- Actavis purchases majority stake in Russian manufacturing facility
- Actavis to acquire Romanian generic oncology specialist, Sindan
- Actavis acquires Alpharma’s Human Generics business
- Fako
- Actavis acquires Denmark's Ophtha
- Actavis acquires Kéri Pharma Generics
- Actavis acquires Higia
- Actavis sells Bulgarian API plant, retains dosage form capacity
- Actavis acquires Amide Pharmaceutical
- Acquisition of Pharma Avalanche
- Actavis expands presence in India
- Actavis acquires Biovena
- Apotex
- Introduction
- Background
- Products
- Financials
- Cangene
- Major developments
- Rwanda issues first notification under WTO Paragraph 6 system
- Akorn and Apotex sign ophthalmics agreement
- Orchid Chemicals & Pharmaceuticals
- BioGeneriX
- Litigation
- Plavix (clopidogrel)
- Allergan sues Apotex for infringement of brimonidine tartrate patents
- Apotex invalidates amlodipine patent, setting off stream of activity
- Unigene/Upsher-Smith file patent infringement lawsuit against Apotex
- Allergan wins Acular patent infringement lawsuit
- Aspen Pharmacare
- Introduction
- Background
- Products
- HIV/AIDS drugs
- South African government ARV tender
- Financials
- Segment Data
- Major developments
- Pharmaceutical firms form new South African industry association
- Mergers, acquisitions and agreements
- Acrux enters oestradiol marketing agreement with Aspen Pharmacare in Australia
- Darunavir access plan with Tibotec
- Lupin and Aspen terminate TB MoU
- Roche
- Oseltamivir
- Saquinavir
- Bristol-Myers Squibb
- Gilead
- Matrix Laboratories
- Fine Chemicals Corporation
- William J Clinton Presidential Foundation
- Eli Lilly
- GlaxoSmithKline
- Strides Arcolab
- Barr Pharmaceuticals
- Introduction
- Background
- Products
- Financials
- Fiscal year 2006
- Major developments
- Barr and Apotex launch Canada’s first generic oral contraceptive
- US Supreme Court denies review of tamoxifen citrate antitrust lawsuit
- Barr successfully acquires Pliva
- Barr and Shire enter three agreements
- Barr/Pliva sign agreement to develop and market generic version of G-CSF in US and Canada
- Barr gains generic fentanyl agreement
- Cipla
- Introduction
- Background
- New Plant Announced, June 2006
- Products
- Financials
- Major developments
- HIV/AIDS
- Thai government in talks with Cipla over antiretroviral ingredients
- AHF and Cipla quarrel over AIDS drugs prices
- Clinton Foundation and UNITAID announce agreements to reduce ARV prices
- Compulsory licensing in Malaysia
- South African antiretroviral tender
- Mergers, acquisitions and agreements
- Akorn signs contract with Cipla for injectable ANDA product
- Akorn and Cipla sign agreement for oral organ transplant rejection drug
- Cipla enters malaria agreement with DNDi
- Cipla to supply API to IVAX
- Cipla Medpro sold to Enaleni
- Pentech Pharmaceuticals
- Avestha Gengraine Technologies
- Morton Grove Pharmaceuticals
- Watson Pharmaceuticals
- Stada, Hexal and Fujisawa
- Dr Reddy’s Laboratories
- Introduction
- Background
- Products
- Financials
- Segment Data
- Active pharmaceutical ingredients and intermediates (API)
- Formulations
- Generics
- Custom pharmaceuticalservices (CPS)
- Critical care andbiotechnology
- Major developments
- Dr Reddy’s opens Manila office
- Dr Reddy’s begins operations in Nigeria
- Dr Reddy’s joins USP’s Pharmaceutical Ingredient Verification Programme
- Dr Reddy’s and Torrent sign Russian lisinopril agreement
- Dr Reddy’s acquires betapharm
- Dr Reddy’s and Argenta announce R&D collaboration
- Dr Reddy's signs agreement to acquire Roche's Mexico API facility
- Perlecan formed as India's first integrated drug-development company; Dr Reddy's invests and
- signs alliance
- Dr Reddy's/Pharmascience sign multi-product agreement
- Dr Reddy's and ICICI form ANDA partnership
- Trigenesis Therapeutics
- Dr Reddy’s Laboratories (Proprietary)
- BMS Laboratories and Meridian Health Care
- American Remedies and Cheminor Drugs
- Pliva
- Leiner Health Products
- Egis
- Introduction
- Background
- Products
- Financials
- Preliminary results for the year ended 30th September, fiscal 2007
- Fiscal 2006 results
- Major developments
- Hungaropharma
- Serdix
- Hospira
- Introduction
- Background
- Products
- Financials
- Segment Results
- Major Developments
- Mayne Pharma
- FTC sets conditions, clearing the way for Hospira’s acquisition of Mayne Pharma
- Hikma and Hospira enter European marketing agreements
- Hospira announces strategic alliance with Pharmalink and Zuellig Pharma in Asia
- KRKA
- Introduction
- Background
- Products
- EMEA recommends MA for Krka product
- Financials
- Major developments
- Facilities
- Slovenia
- Russia
- Poland
- Representative offices
- Litigation
- Simvastatin
- Atorvastatin
- Enalapril
- Lannett
- Introduction
- Background
- New facility leased, 2006
- Products
- Financials
- Major developments
- Lannett acquires unnamed API supplier
- PharmaSeed Bioservices
- Olive Healthcare
- Azad Pharma
- Wintac
- Orion Pharma
- Unichem Laboratories
- Jerome Stevens Pharmaceutical
- Merck Generics
- Introduction
- Background
- Alphapharm
- Generics (UK)
- Genpharm
- Merck Generics (South Africa)
- Merck Dura
- Dey Inc
- Products
- Financials
- Major developments
- Mylan agrees to acquire Merck Generics for 4 billion euros
- Glenmark and Merck Generics form European marketing agreement
- Merck KGaA purchases Spain's Prasfarma
- NM Pharma
- Litigation
- Generics (UK)
- Mylan
- Introduction
- Background
- Products
- Financials
- Segment Data
- Total Revenues by Geographic Region
- Major developments
- Mylan agrees to acquire Merck Generics for 4 billion euros
- Matrix Laboratories
- King Pharmaceuticals merger called off
- Par Pharmaceuticals
- Introduction
- Background
- Kali Laboratories
- Products
- Financials
- Major Developments
- Hana Biosciences licenses North American ondansetron rights to Par Pharmaceutical
- IntelliPharmaCeutics announces equity investment by Par Pharmaceutical
- AstraZeneca/Par enter agreement for generic version of Toprol-XL
- Spectrum Pharmaceuticals
- Par divests FineTech
- Bradley and Par enter licensing agreement for Adoxa
- MN Pharmaceuticals
- Orchid Chemicals & Pharmaceuticals
- Perrigo
- Introduction
- Background
- Products
- Financials
- Segment Sales
- Major developments
- Perrigo divests two facilities
- Perrigo acquires Qualis
- Perrigo acquires generic dermatological products from Glades
- Dexcel Pharma Technologies
- Agis Industries
- Collaboration with Bentley Pharmaceuticals
- Litigation
- Adams receives notice of Paragraph IV certification against patents for Mucinex SE
- Triamcinolone (Barr Laboratories)
- Connetics
- FTC investigation
- Phenylpropanolamine
- Pliva
- Introduction
- Background
- Products
- Biosimilars
- Financials
- Segment Results
- Revenues by Region
- Major developments
- Pliva to acquire ORCApharm
- Barr successfully acquires Pliva
- Pliva signs agreement with Unichem for new products in the US
- Uso Racional
- Pliva exits proprietary business
- Pliva's AWD.pharma divests manufacturing plant
- Pliva subsidiary divests branded product, terminates agreements with Legacy Pharma
- Pliva signs new bulk azithromycin supply agreement with Pfizer
- Ranbaxy
- Introduction
- Background
- Products
- Antiretrovirals
- Ranbaxy forms JV in South Africa to market antiretrovirals
- Gilead signs eight TDF agreements with Indian companies
- Financials
- Segment Data
- Geographic Segment
- Major developments
- Ranbaxy acquires dermatology brands from Bristol-Myers Squibb
- Ranbaxy signs first biosimilars agreement
- Ranbaxy signs new R&D agreement with GlaxoSmithKline
- Ranbaxy acquires Be-Tabs for US$70 million
- Ipca and Ranbaxy sign deal for US market
- Ranbaxy signs Canadian licensing and supply agreement
- Ranbaxy to acquire GSK's Mundogen generic business in Spain
- Ranbaxy completes Terapia acquisition
- Ranbaxy forms strategic oncology partnership with Zenotech
- Ranbaxy to co-market Ferring's desmopressin in India
- Ranbaxy and Nippon Chemiphar consolidate relationship
- Ranbaxy to market Lupin's TB brands in Africa
- Ranbaxy acquires generic product portfolio from Efarmes
- UK Department of Health legal action settled
- ratiopharm
- Introduction
- Background
- BioGeneriX
- Merckle Biotec
- Merckle
- PulmoTec
- ratiopharm direct
- Products
- Financials
- Major developments
- German bribery investigation
- Mergers, acquisitions and agreements
- Hikma acquires ribosepharm from ratiopharm
- BioGeneriX and Neose update on biosimilar collaboration
- Orbus signs agreement with ratiopharm Canada
- IntelliPharmaCeutics enters generic agreements with ratiopharm
- Magnafarma
- BioGeneriX signs agreement with Cangene
- Ribosepharm
- Gedeon Richter
- Introduction
- Background
- Products
- Financials
- Segment Results
- Geographic Segment Data
- Major developments
- Gedeon Richter acquires Romania’s Dita Group
- Themis Medicare India starts trial production at Vapi site
- US deal with KV Pharmaceutical
- Consortium bid for Hungaropharma successful
- GZF Polfa
- Biogen International
- Sandoz
- Introduction
- Background
- Production Facilities
- Sandoz Canada to invest C$80 million in Boucherville facilities
- Products
- Financials
- Lek
- Major developments
- EU epoetin alpha approval
- Omnitrope approved in EU and USA
- EU
- USA
- Momenta enters expanded collaboration agreement with Sandoz
- Lek opens new facility in Slovenia
- Sandoz completes purchase of Hexal and Eon Labs
- Sabex
- Durascan
- Amifarma
- Sawai Pharmaceutical
- Introduction
- Background
- Products
- New government supply rules, 2006
- Financials
- Major developments
- Towa, Sawai and Nichi-iko sign agreement for stable supply of generic products
- Medisa Shinyaku
- Nihon Schering’s Mobara factory
- Japan Generic Drug Research Group
- Stada Arzneimittel
- Introduction
- Background
- Products
- EPO submitted to EMEA
- Financials
- Segment Data
- Geographic Segment Data
- Major developments
- Stada reorganises biosimilar projects; Hospira to acquire erythropoietin rights
- Mergers, acquisitions and agreements
- Forum Bioscience Group
- Makiz
- Hemofarm
- Stada sells US subsidiary to DAVA
- ProStrakan signs branded generic agreement with Genus Pharmaceuticals
- Beijing Center-Lab Pharmaceutical, majority stake
- Advancis enters amoxicillin PULSYS agreement with Stada's Clonmel Healthcare
- Strides enters agreement with Stada in the US
- Stada acquires Portuguese generics supplier
- Orchid enters US market agreement with Stada Pharmaceuticals
- Stada acquires Nizhpharm
- Teva Pharmaceutical Industries
- Introduction
- Background
- Products
- Financials
- Segment Data
- Geographic Segment
- Major developments
- BioSante and Teva restart testosterone product development
- Teva and Synerx form US marketing partnership
- Teva signs biopharmaceuticals agreement with Procognia (Israel)
- Teva increases stake in Hualida
- Teva completes IVAX acquisition; Par and Barr benefit
- Teva and Barr sign agreement covering fexofenadine
- Teva and TransPharma sign transdermal drug delivery agreement
- Dorom
- Microbia
- Sicor
- Impax
- Litigation
- Federal appeals court upholds Lexapro patent decision
- Novartis' motion for preliminary injunction against Teva's Lotrel generics denied
- Court rules in Eisai's favour over Aciphex ANDAs
- Pfizer wins Celebrex patent challenge by Teva
- Biovail reaches comprehensive settlement related to Wellbutrin XL
- Teva files patent infringement complaints against sertraline manufacturers
- Teva and Pfizer reach agreements for anti-infective and cancer products
- Impax prevails in ALZA's appeal over generic Ditropan XL
- Purdue and Teva agree deal to end OxyContin patent lawsuit
- Court of Appeals rules in Teva's favour on Biaxin XL preliminary injunction
- Alcon files patent infringement suit against Teva regarding Vigamox
- Esomeprazole magnesium
- Adderall
- Fexofenadine
- Modafinil
- Missouri AG alleges firms involved in AWP inflation scheme
- Donezepril hydrochloride
- Quetiapine fumarate
- Gatifloxacin tablets
- Lovenox
- Astellas/ITEM/King file lawsuit against Teva for Adenoscan patent infringement
- Moexipril
- Towa Pharmaceutical
- Introduction
- Background
- Products
- Financials
- Major developments
- Towa, Sawai and Nichi-iko reach supply agreement
- Eisai's lawsuit against manufacturers/distributors of generic Selbex dismissed
- Japanese Generic companies form agreement for stable generic supply
- Watson Pharmaceuticals
- Introduction
- Background
- Andrx
- Products
- Generics Division
- Brand Division
- Distribution Division
- Financials
- Segment Results
- Major developments
- Depomed enters promotion agreement with Watson
- Sandoz' ANDA for generic Toprol-XL approved further to agreement with Watson
- Watson completes acquisition of Sekhsaria Chemicals
- Watson completes acquisition of Andrx
- Other acquisitions and collaborations
- Watson to distribute OxyContin authorised generic
- Interpharm and Watson commence ibuprofen manufacturing and supply agreement
- Bupropion authorised generic agreement with GSK
- Winthrop Pharmaceuticals
- Introduction
- Background
- Czech Republic
- France
- Germany
- Portugal
- United Kingdom
- Products
- Financials
- Major Developments
- sanofi-aventis acquires 25% of Zentiva’s shares
- Wockhardt
- Introduction
- Background
- Wockhardt to build global manufacturing hub in India
- Products
- Financials
- Major developments
- Wockhardt to raise up to US$800 million to fund overseas acquisitions
- Pharmaceutical plants
- Barotiwala, India
- Luton, United Kingdom
- Aurangabad, India
- Joint Ventures
- Mergers, acquisitions and agreements
- Negma Laboratories
- Pinewood Laboratories
- Li-Taka Pharmaceuticals
- esparma GmbH
- CP Pharmaceuticals Ltd
- Ranbaxy
- Zentiva
- Introduction
- Background
- Products
- Financials
- Major developments
- Zentiva to acquire control of Eczacibasi's generic pharmaceuticals business
- Zentiva acquires Hungarian generic products from sanofi-aventis
- sanofi-aventis
- Sicomed
- Zydus Cadila
- Introduction
- Background
- Products
- Financials
- Major Developments
- Quimica e Farmaceutica Nikkho do Brasil
- Zydus acquires Japan’s Nippon Universal Pharmaceutical
- Zydus acquires Liva Healthcare
- Evolupharn and Aerocid
- Joint venture with Bharat Serums and Vaccines
- Joint venture with Mayne Pharma
- Venus Remedies
- Alliance with Mallinckrodt
- MoU with Zambon
- Alpharma France
- Merger into Cadila Healthcare
- Litigation
- Ribavirin
- VOLUME II
- Overview
- Population
- GDP per capita
- Health Expenditure
- Total Pharmaceutical Expenditure
- Generic Pharmaceutical Expenditure
- Generic Market Projections
- Australia
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Regulation
- Intellectual Property
- US Free Trade Agreement, Generic Amendments
- Parliament passes patent springboarding Bill
- Pricing & reimbursement
- Rise in Co-payment rates, 2005
- Therapeutic Group Premiums
- US Free Trade Agreement
- Government announces new pricing measures for newly listed drugs
- Government announces further PBS reforms, 2006
- Manufacturing
- Alphapharm
- Genepharm Australasia
- Mayne Pharma (Hospira)
- Sigma Pharmaceuticals Pty Ltd.
- Brazil
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Production of Oral Generic Contraceptives & Hormones
- More Uniform Market Penetration Across all the Regions
- Unsustainable Reliance on Original HIV/AIDS Medicines
- Intellectual Property
- Lobbying Against Patent Extensions in the Pipeline System
- Deal Agreed to Reduce the Price of Abbott‟s Kaletra
- Upcoming Patent Expiries
- Pricing & reimbursement
- Implications for the Industry
- Excessive Taxes on Drugs
- New Drug Discounts in the Public Sector
- Pricing of Generic Medicines
- Manufacturing
- ALANAC
- ALFOB
- Pró-Genéricos
- Aché
- Americano de Farmacoterapia (FARMASA)
- Arrow (Erowlabs)
- Brainfarma
- Cimed
- Cristália
- EMS Sigma Pharma
- Eurofarma
- Hipolabor
- LAFEPE
- Medley
- Neo Química
- Prati, Donaduzzi
- Teuto
- União Química
- Multinational Producers of Generic Medicines In Brazil
- Apotex
- Mepha - ratiopharm
- Merck KGaA
- Ranbaxy
- Sandoz
- Canada
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Study: generic savings not passed onto customers
- Outlook & Projections
- Intellectual Property
- New rules come into effect, October 2006
- Canada‟s Access to Medicine Regime
- Pricing & reimbursement
- PMPRB issues first report on non-patented prescription drug prices
- Price increases between 2004 and 2005
- Study comparing drugs prices in Canada and the USA released
- Provincial Formularies
- The Quebec 15-year rule
- Ontario Bill 102
- Drug Insurance Programmes
- Manufacturing
- Apotex
- Genpharm
- Novopharm
- Orbus Pharma
- Pharmascience
- Ranbaxy
- ratiopharm
- Sandoz
- France
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Outcomes of the New Reference Pricing System
- Increasing Prescribing of Generics
- Generic Drugs to Reduce Health Expenditure by 912 Million Euros in 2006
- France Transposes EU Pharmaceutical Directive
- Pharmacists Associations Agree New Generics Target for 2007
- Intellectual Property
- Supplementary Protection Certificates
- Pricing & reimbursement
- Pricing
- Pricing of Reimbursable Medicines in the Retail Pharmacy Market
- Price Revisions
- Pricing Activity
- Pharmacy Margins
- Reference Pricing (TFR)
- Pricing of Hospital Medicines
- Reimbursement
- Manufacturing
- Local Manufacturers
- Arrow Génériques
- Biogaran
- Bouchara-Recordati
- EG-Labo
- Merck Génériques
- Ranbaxy
- ratiopharm
- Sandoz
- Teva
- Winthrop
- Wockhardt
- Zydus France
- Germany
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- GKV Generic Use
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Pricing
- Reimbursement
- AOK negotiates pharmaceutical discount contracts
- Generic Substitution Policies
- Compulsory Manufacturer Rebates
- AVWG, 2006
- Manufacturing
- 1A Pharma GmbH
- AbZ-Pharma GmbH
- Acceco Arzneimittel GmbH
- Aliud Pharma
- Actavis Deutschland
- AWD.pharma
- Basics
- betapharm
- CT-Arzneimittel
- Heumann Pharma Generics/Torrent Pharmaceuticals
- Hexal
- Hospira Deutschland GmbH
- Merck Dura
- Neuraxpharm
- ratiopharm
- Ribosepharm
- Sandoz
- Stada Arzneimittel
- Teva Generics
- Winthrop Arzneimittel
- Italy
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- National Supplementary Protection Certificate
- Pricing & reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
- Reimbursement
- Manufacturing
- ASSOGENERICI
- Local Manufacturers
- Angenerico
- DOC Generici
- Eurogenerici
- Hexan
- Merck Generics Italia
- Pliva Pharma
- Ranbaxy
- ratiopharm Italia
- Sandoz
- Teva Pharma Italia
- Japan
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Generic substitution plans
- Outlook & Projections
- Regulations
- Generic regulation, 2005
- Intellectual Property
- Data Exclusivity
- Exclusion of Use
- Patent term extensions
- Pricing & reimbursement
- Yakkasa
- Price reductions
- Generic drug pricing
- Manufacturing
- MHLW Stable Supply Requirements, 2006
- Overseas players
- Netherlands
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Price reductions, 2005
- Manufacturing
- Actavis
- Centrapharm BV
- Disphar International BV
- Katwijk Farma BV
- Merck Generics
- Pharmachemie BV
- Ratiopharm Nederland
- Sandoz
- Russia
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Intellectual Property
- Counterfeit Medicines
- Pricing & reimbursement
- Drug Pricing
- DLO, Federal Drug Supply System
- Manufacturing
- Akrikhin
- Bryntsalov A
- JSC Farmacon
- Grindex Rus
- KRKA
- Makiz
- Nizhpharm
- Otechestvennye Lekarstva (Erka Farm)
- Pharmstandard
- Veropharm
- Yugrafarm
- ZiO Zdorovje
- Spain
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Outlook & Projections
- Biosimilars‟ Substitution, Not a Viable Option in Spain
- Regional INN Prescribing
- SWOT
- Intellectual Property
- European Supplementary Protection Certificate
- Pricing & reimbursement
- Co-Payments
- RPS Analysis
- Generic Pricing
- Manufacturing
- AESEG
- Local Manufacturers
- Adamed
- Alter
- Barr
- Cantabria Pharma
- Cinfa
- Combino Pharm
- DOMAC
- Dr Reddy‟s
- Kern Pharma
- Mabo-Farma
- Merck
- Normon
- Pharmagenus
- Ranbaxy
- ratiopharm
- Sandoz
- Stada
- Teva
- Switzerland
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- OKP Market Data, 2006
- Outlook & Projections
- Intellectual Property
- Pricing & reimbursement
- Generic pricing
- Generic pricing survey, 2006
- Generic/Brand price comparisons, 2007
- Generic reimbursement
- Manufacturing
- Cimex
- Helvepharm
- Mepha Pharma
- Sandoz Pharmaceuticals
- Spirig
- Streuli Pharma
- United Kingdom
- Introduction
- Pharmaceutical Market
- Market Structure
- NHS Prescription Medicines Market
- Generic Market
- Size
- Generic Prescribing
- Scotland
- Wales
- Outlook & Projections
- Regulation
- Marketing Authorisations in 2006
- Intellectual Property
- Supplementary Protection Certificates
- Pricing & reimbursement
- Pricing
- Unbranded Generic Pricing
- 2005 generics reimbursement scheme
- Generic price reductions for four major drugs
- DOH Holds consultations regarding branded generics in the PPRS
- Reimbursement
- Investigations into price fixing
- Department of Health
- Goldshield, Ranbaxy and Merck settle DOH claims
- Serious Fraud Office
- Manufacturing
- Actavis
- Arrow Generics
- Bristol Laboratories
- Crescent Pharma
- Dr Reddy‟s
- Focus Pharmaceuticals
- Generics (UK)
- Genus Pharmaceuticals
- Goldshield Pharmaceuticals
- Kent Pharmaceuticals
- Perrigo
- Pliva Pharma (Barr Laboratories)
- Ranbaxy
- ratiopharm
- Rosemont Pharmaceuticals
- Sandoz
- Teva Pharmaceuticals
- Winthrop Pharmaceuticals
- Wockhardt
- USA
- Introduction
- Pharmaceutical Market
- Generic Market
- Size
- Wal-Mart begins generic drug price war?
- FTC reports summary of pharmaceutical company agreements filed in FY2006
- Outlook & Projections
- Intellectual Property
- Hatch-Waxman
- Hatch Waxman reform, 2003
- Bolar Amendment
- Patent Reform Act 2007
- Wider patent reform?
- Major Product Approvals
- Generic Initiative for Value and Efficiency (GIVE)
- ANDAs Approved in 2006
- ANDAs Approved in 2007 (to September)
- Forthcoming Patent Expiries
- Atorvastatin
- Clopidogrel
- Pricing & reimbursement
- Public Drug Procurement
- Medicaid
- Average Wholesale Price (AWP)
- Medicare
- H.R (Medicare Prescription Drug, Improvement, and Modernization Act of 2003)
- State pricing/reimbursement moves
- California drug plan signed into law
- Manufacturing
- Sources
- Directory
- Regulators
- Industry Associations
AbstractKey company, market and product information
To understand the generic market, Espicom, the publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2008. Packed with facts, figures, analysis and statistics, the new 700 page edition - now presented in 2 volumes - provides the most thorough analysis available on generic markets, products and companies and the issues they face.
The changing face of the generics industry
The pace of corporate consolidation grows ever faster with, most notably this year, Mylan’s success in winning Merck Generics. But that was just one event in the ongoing global rationalisation of the generics industry.
Emerging European markets present good opportunities
Generic companies and investors have spent much time in looking at new market opportunities often in emerging economies such as Brazil and Russia. However, France, Italy and Spain are all undergoing significant double digit growth with well organised and regulated operating environments.
Industry consolidation, emerging market opportunities, the latest on biosimilars plus much, much more!
Published in December 2007, this report draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:
- Industry consolidation and the emergence of “super” generic companies
- Generic market growth - but where?
- Biosimilars: more products and development in Europe and elsewhere
- Authorised generics and other 180-day exclusivity issues in the US - a definite trend
- Key legal challenges
- The political and funding background
- Intellectual property issues
This report will enable you to understand the threats and opportunities that are shaping this rapidly evolving marketplace.
This study is not presented with any quarterly updates.
Please note, this file is delivered as a Zip file.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
